Harbour BioMed and Insilico Medicine: Revolutionizing Antibody Discovery with AI

Harbour BioMed (HKEX: 02142) and Insilico Medicine have joined forces in a strategic collaboration to advance AI-driven antibody discovery and development. This alliance combines Harbour BioMed's industry-leading technology platform, proprietary dataset, and extensive expertise in antibody development with Insilico Medicine's advanced capabilities in designing integrated AI-driven drug discovery and development platforms. Together, they aim to jointly develop the next-generation AI-powered antibody application and collaborate on early-stage drug discovery programs targeting novel, specific antibodies.



Harbour BioMed's proprietary Harbour Mice® platform enables the generation of fully human monoclonal antibodies in both conventional (H2L2) and heavy chain-only (HCAb) formats, eliminating the need for additional engineering or humanization. The HCAb technology, in particular, produces unique, fully human heavy chain-only antibodies that are approximately half the size of conventional IgGs, offering significant advantages for next-generation antibody therapies. With a clinically validated and globally recognized platform, Harbour BioMed has applied its technology in more than 250 drug discovery programs across various therapeutic areas, establishing itself as a leader in the field of biotherapeutics.

Insilico Medicine has previously showcased the capability of its proprietary AI platform to significantly reduce cost and improve efficiency in the early stages of small molecule drug discovery and development. Since 2021, the company has established a wholly-owned pipeline of 30 assets powered by its Pharma.AI platform, 10 of which have received IND clearance, setting a benchmark for AI-driven drug discovery and development. In July 2024, Insilico introduced Generative Biologics, an AI-powered tool for de novo protein engineering, designed to accelerate the development of next-generation biologics. Moving forward, the company plans to leverage real-world case studies to further refine and advance the application through ongoing enhancements and iterative improvements.

By combining Harbour BioMed's validated Harbour Mice® platform with advanced generative AI approaches, the collaboration aims to further streamline antibody discovery, enhance candidate selection, and ultimately bring innovative therapies to patients more efficiently. The combination of advanced machine learning models with biological expertise enables the prediction of antibody structures, identification of binding sites, and design of candidates with enhanced specificity, efficacy, and safety. High-quality dataset and wet-lab validation are critical components in this process, and Harbour BioMed's expertise in these areas makes it an ideal partner for Insilico Medicine.

Together, Harbour BioMed and Insilico Medicine aim to build the next generation AI-driven antibody platforms and deliver breakthrough antibody therapies to address critical healthcare needs in immunology, oncology, and neuroscience. By leveraging their respective technological strengths and collaborating on early-stage drug discovery programs, the two companies can accelerate the development of innovative therapeutic solutions for unmet medical needs.



In conclusion, the strategic collaboration between Harbour BioMed and Insilico Medicine is poised to revolutionize the antibody discovery and development landscape by harnessing the power of AI and advanced technological platforms. This alliance holds great promise for delivering innovative therapeutic solutions to address critical healthcare needs in immunology, oncology, and neuroscience.